Hepatic function: albumin ≥ 2.5 g/dL, serum bilirubin ≤ 1.5 × N (except if Gilbert's Syndrome) , aminotransferases ≤ 3 × N (≤ 5 × N if hepatic metastases)
Renal function: serum creatinine ≤ 1.5 mg/dL or clearance of creatinine ≥ 40 ml/min
Women without endometrial pathology
Ability to provide written informed consent before the start of any study specific procedures
You may not be if
Age \< 18 years old
Pre-menopausal, pregnant or pregnant or breast feeding females
Patient who should exclusively be treated by chemotherapy
Women previously treated with chemotherapy but not by AIs
Women previously treated by tamoxifen for their metastatic breast cancer
Concurrent disease or condition that may interfere with study participation, or any serious medical disorder that would interfere with the subject's safety (for example, active or uncontrolled infection or any psychiatric condition prohibiting understanding or rendering of informed consent)
Any pathology, including severe psychiatric or psychologic disease that may harm patient's safety or participation in the study
Serious or not cured or unstable toxicity due to the administration of another drug being involved in clinical trials
Uncontrolled cardiovascular pathologies
Previous history of thromboembolic event like deep vein thrombosis or pulmonary embolism recorded within one year before the inclusion date
Active uncontrolled infection
Existence of an increased risk of thromboembolic event, apart from the metastatic cancer condition, such as:
* known presence of antiphospholipid antibody
* family history of thrombophilia
* existence of any clinical, genetic, or biological abnormality which can increase the risk of thromboembolic event according to the
Participation to a clinical trial at least 4 weeks prior the start of the study
Clareo Health | Evaluation of the Efficacy of Estramustine in Patient With Breast Cancer Progression After Treatment With Aromatase Inhibitor.
